Stocks To Watch: PepsiCo, Inc. (NYSE:PEP); Esperion Therapeutics, Inc. (NASDAQ:ESPR); General Motors Company (NYSE:GM)
Dallas, Texas, 10/02/2014 (ustrademedia) – PepsiCo, Inc. (NYSE:PEP) announced on 1st October that it launching a new cola based drink in U.S. The new product is called Pepsi True. The beverage is being positioned as a drink which is made sweet using real sugar. To add flavour, the beverages giant has added Stevia leaf into the mix. True to its Chairman of the Board, Chief Executive Officer CEO Indra K. Nooyi commitment earlier this year to make its drinks healthier, the drink is said to be contain 30 percent less sugar in comparison to regular serving of Pepsi. It also cuts out the use of “high-fructose corn syrup or artificial sweeteners” the company press release noted.
Emerging drug maker Esperion Therapeutics, Inc. (NASDAQ:ESPR) on 1st October announced positive top-line data from its phase 2 clinical trials conducted on its drug candidate ETC-1002. The drug is designed to treat hypercholesterolemia. The drug maker disclosed that the data pointed to the successful meeting of previously set end point goals. The tests found that the “LDL-cholesterol” levels were found to be significantly lower in patients who had been administered the drug candidate in comparison to those treated with ezetimibe. The drug maker had hosted a conference call yesterday to announce the clinical test findings.
General Motors Company (NYSE:GM) Chief Executive Officer Mary T. Barra indicated on 1st October a broad outline of her future roadmap for the automaker. Her plans are designed to keep the car maker ahead of its competition in U.S. Her comments were shared with GM employees in Michigan. She indicated that the plans if implemented effectively would win the car maker new customers for life. This in turn will go a long way to increase share holder value, the CEO opined. The plan involves new products becoming significant revenue generators in FY15 and beyond.